Skip to content

Merck gets FDA turndown on diabetes med

April 7, 2017

Merck & Co. Inc. shares MRK, -0.52% fell 1.5% in premarket trade Friday, after the company said it received a Complete Response Letter from the U.S. Food and Drug Administration regarding its application to include data on cardiovascular effects in the prescribing information of medicines using Sitagliptin, a treatment for type 2 diabetes. A CRL is a communication from the FDA that a drug application will not be approved in its current form. Merck said it is reviewing the letter and will discuss its next steps with the FDA. Merck shares have gained 7% in 2017, while the S&P 500SPX, +0.19% has gained 5%.

http://on.mktw.net/2oQjuJa

Advertisements

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: